



Wan Ahmad Kamil, W. N. I., Takebayashi, Y., Findlay, J., Heesom, K. J., Jiménez-Castellanos, J. C., Zhang, J., ... Avison, M. B. (2018). Prediction of fluoroquinolone susceptibility directly from whole-genome sequence data by using liquid chromatography-tandem mass spectrometry to identify mutant genotypes. *Antimicrobial Agents and Chemotherapy*, 62(3), e01814-01817. <https://doi.org/10.1128/AAC.01814-17>

Peer reviewed version

Link to published version (if available):

[10.1128/AAC.01814-17](https://doi.org/10.1128/AAC.01814-17)

[Link to publication record in Explore Bristol Research](#)

PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via ASM at <http://aac.asm.org/content/early/2017/12/12/AAC.01814-17.abstract> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/pure/about/ebr-terms>

Table S1. Clinical Isolates used in this study

Isolate ID	Organism source	Date of Isolation
KP1	Blood Culture	12/04/2016
KP2	Blood Culture	08/03/2016
KP3	Tissue	10/01/2016
KP4	Tissue	07/12/2015
KP5	Blood Culture	05/10/2015
KP6	Blood Culture	25/09/2015
KP7	Blood Culture	01/09/2015
KP8	Ascitic Fluid	23/02/2015
KP9	Tissue/Kidney Stone	05/12/2014
KP10	Blood Culture	27/10/2014
KP11	Screening Swab	10/10/2014
KP12	Blood Culture	01/10/2014
KP13	Groin swab	02/07/2014
KP14	Wound swab	11/06/2014
KP15	Blood Culture	20/05/2014
KP16	Blood Culture	20/04/2014
KP17	Sputum	19/03/2014
KP18	Catheter urine	18/02/2014
KP19	Catheter urine	17/10/2013
KP20	Sputum	01/08/2013
KP21	Sputum	30/07/2013
KP22	Blood Culture	27/07/2013
KP23	Wound swab	23/07/2013
KP24	Mid-stream urine	23/07/2013
KP25	Blood Culture	22/07/2013
KP26	Mid-stream urine	03/07/2013
KP27	Central Line Tip	17/04/2013
KP28	Bronchio-alveolar Lavage (BAL)	11/03/2013
KP30	Blood Culture	07/08/2012
KP31	Blood Culture	06/07/2016
KP32	Tissue	05/07/2016
KP33	Pus	05/07/2016
KP34	Tissue	28/06/2016
KP38	Blood Culture	21/06/2016
KP40	Blood Culture	09/06/2016

KP46	Tissue	22/04/2016
KP47	Blood Culture	22/04/2016
KP48	Peritoneal Fluid	01/04/2016
KP50	Pus	23/03/2016
KP59	Blood Culture	25/02/2016

Table S2. PCR Primers used in this study

Primer	Sequence (5' to 3')	Reference
gyrA - F	AATATGCGCCATCAGCCC	(S1)
gyrA - R	TGCGAGAGAAATTACACC	(S1)
parC - F	ATGAGCGATATGGCAGAGC	This work
parC - R	CCACTTCCCGCAGGTTGT	This work
oqxR - F	TTCCTGACGCCGGTGTTTTA	(S2)
oqxR - R	CTGCGGTGCCAAAAAGAACA	(S2)
ramR - F	CTGCAGTGCCCGGTGAACCCTGGCGT	(S3)
ramR - R	CTGCAGATTTGCTGATTCAGCAGCGAC	(S3)
Qnr synthesis	From: GAGCGCTTGTGTCGCTACAT To: GGTTGCTTCATGGGCAA	As Accession number AY070235.1
AAC-6'-Ib-cr synthesis	From: GAGCAAACGATCAATGCG To: AAGCCTAGCCAATTTGCTAGG	As Accession number JF775514.1

Table S3. Mutations identified in the *oqxR*

Mutant/Isolate	Amino acid position and changes
<i>oqxR1</i>	Tyr109STOP
<i>oqxR2</i>	Leu89FS
<i>oqxR3</i>	Ala37Glu
<i>oqxR4</i>	Ala133Val
<i>oqxR5</i>	Arg93Cys
<i>oqxR6</i>	Glu85STOP
<i>oqxR7</i>	Gln21STOP
<i>oqxR8</i>	Glu116STOP
<i>oqxR9</i>	Asp3Glu
<i>oqxR10</i>	Ala133Pro
<i>oqxR11</i>	Ala37Glu
<i>oqxR12</i>	Gly63 ins SIHLGRNG
KP9	Glu24STOP
KP12	Asp3Tyr
KP20	Ala19Val
KP28	Leu76FS
KP30	Val130Ala

Effects on OqxR sequence of mutations identified in *oqxR* in Ecl8 mutants (alleles *oqxR1* to 12) or in the *K. pneumoniae* clinical isolates (KP9, 12 etc). All these mutations have been shown to result in loss of function, and so OqxAB hyper-production.

Table S4: Disc susceptibility testing according to CLSI protocol (26) for *K. pneumoniae* Ecl8 and mutants determining the effect of acquisition events on Fluoroquinolone susceptibility.

Parental strain ^a , mutation (transformed plasmid)	Susceptibility/Non-Susceptibility to				Mutation/Transformation
	CIP	LEV	NOR	OFL	
Ecl8	S	S	S	S	Wildtype
Ecl8 (pEX-K4)	S	S	S	S	Vector only
Single acquisition events					
<i>gyrA1</i>	S	S	S	S	GyrA:Ser83Phe
<i>gyrA2</i>	S	S	S	S	GyrA Ser83Tyr
<i>gyrA3</i>	S	S	S	S	GyrA Asp87Tyr
<i>oqxR1</i>	S	S	S	S	OqxR:Tyr109STOP
<i>oqxR2</i>	S	S	S	S	OqxR:Leu89FS
<i>oqxR3</i>	S	S	S	S	OqxR:Ala37Glu
<i>oqxR4</i>	S	S	S	S	OqxR:Ala133Val
$\Delta ramR$	S	S	S	S	deleted RamR
<i>ramR</i>	S	S	S	S	RamR:Thr124Pro
(<i>qnrA1</i>)	S	S	S	S	QnrA1
(<i>aac(6')-Ib-cr</i>)	S	S	S	S	Aac(6')-Ib-cr
Double acquisition events					
<i>oqxR1 + gyrA2</i>	NS	NS	NS	NS	OqxR:Tyr109STOP + GyrA:Ser83Tyr
$\Delta ramR + gyrA1$	NS	NS	S	NS	deleted RamR + GyrA:Ser83Phe
$\Delta ramR + oqxR5$	S	S	NS	S	deleted RamR + OqxR:Arg93Cys
(<i>qnrA1 + aac(6')-Ib-cr</i>)	S	S	S	S	QnrA1+ Aac(6')-Ib-cr
<i>gyrA1</i> (pEX-K4)	S	S	S	S	GyrA:Ser83Phe Vector only
<i>gyrA1 (qnrA1)</i>	S	S	S	S	GyrA:Ser83Phe + QnrA1
<i>gyrA1 (aac(6')-Ib-cr)</i>	S	S	S	S	GyrA:Ser83Phe + Aac(6')-Ib-cr

<i>oqxR1</i> (pEX-K4)	S	S	S	S	OqxR:Tyr109STOP Vector only
<i>oqxR1</i> (<i>qnrA1</i>)	NS	NS	NS	NS	OqxR:Tyr109STOP + QnrA1
<i>oqxR1</i> (<i>aac(6')-Ib-cr</i>)	S	S	S	S	OqxR:Tyr109STOP + Aac(6')-Ib-cr
Δ <i>ramR</i> (pEX-K4)	S	S	S	S	deleted RamR Vector only
Δ <i>ramR</i> (<i>qnrA1</i>)	NS	NS	NS	NS	deleted RamR + QnrA1
Δ <i>ramR</i> (<i>aac(6')-Ib-cr</i>)	S	S	S	S	deleted RamR + Aac(6')-Ib-cr

Triple acquisition events

Δ <i>ramR</i> + <i>oqxR5</i> + <i>gyrA1</i>	NS	NS	NS	NS	deleted RamR + OqxR:Arg93Cys + GyrA:Ser83Phe
<i>gyrA1</i> (<i>qnrA1</i> + <i>aac(6')-Ib-cr</i>)	NS	S	NS	S	GyrA:Ser83Phe + QnrA1 + Aac(6')-Ib-cr
<i>oqxR1</i> (<i>qnrA1</i> + <i>aac(6')-Ib-cr</i>)	NS	S	NS	NS	OqxR:Tyr109STOP + QnrA1 + Aac(6')-Ib-cr
Δ <i>ramR</i> (<i>qnrA1</i> + <i>aac(6')-Ib-cr</i>)	NS	S	S	S	deleted RamR + QnrA1+ Aac(6')-Ib-cr
<i>oqxR1</i> + <i>gyrA2</i> (pEX-K4)	NS	NS	NS	NS	OqxR:Tyr109STOP + GyrA:Ser83Tyr Vector only
<i>oqxR1</i> + <i>gyrA2</i> (<i>qnrA1</i>)	NS	NS	NS	NS	OqxR:Tyr109STOP + GyrA:Ser83Tyr + QnrA1
<i>oqxR1</i> + <i>gyrA2</i> (<i>aac(6')-Ib-cr</i>)	NS	NS	NS	NS	OqxR:Tyr109STOP + GyrA:Ser83Tyr + Aac(6')-Ib-cr
Δ <i>ramR</i> + <i>gyrA1</i> (pEX-K4)	NS	NS	S	NS	deleted RamR + GyrA:Ser83Phe Vector only
Δ <i>ramR</i> + <i>gyrA1</i> (<i>qnrA1</i>)	NS	NS	NS	NS	deleted RamR + GyrA:Ser83Phe + QnrA1
Δ <i>ramR</i> + <i>gyrA1</i> (<i>aac(6')-Ib-cr</i>)	NS	S	NS	S	deleted RamR + GyrA:Ser83Phe + Aac(6')-Ib-cr
Δ <i>ramR</i> + <i>oqxR5</i> (pEX-K4)	S	S	S	S	deleted RamR + OqxR:Arg93Cys Vector only
Δ <i>ramR</i> + <i>oqxR5</i> (<i>qnrA1</i>)	NS	NS	NS	NS	deleted RamR + OqxR:Arg93Cys + QnrA1
Δ <i>ramR</i> + <i>oqxR5</i> (<i>aac(6')-Ib-cr</i>)	S	S	S	S	deleted RamR + OqxR:Arg93Cys + Aac(6')-Ib-cr

Quadruple acquisition events

<i>oqxR1 + gyrA2</i> (<i>qnrA1 + aac(6')-Ib-cr</i>)	NS	NS	NS	NS	OqxR:Tyr109STOP + GyrA:Ser83Tyr + QnrA1 + Aac(6')-Ib-cr
Δ <i>ramR + gyrA1</i> (<i>qnrA1 + aac(6')-Ib-cr</i>)	NS	NS	NS	NS	deleted RamR + GyrA:Ser83Phe + QnrA1 + Aac(6')-Ib-cr
Δ <i>ramR + oqxR5 +</i> (<i>qnrA1 + aac(6')-Ib-cr</i>)	NS	NS	NS	NS	deleted RamR + OqxR:Arg93Cys + QnrA1 + Aac(6')-Ib-cr
Δ <i>ramR + oqxR5 + gyrA1</i> (<i>pEXK4</i>)	NS	NS	NS	NS	deleted RamR + OqxR:Arg93Cys + GyrA:Ser83Phe Vector only
Δ <i>ramR + oqxR5 + gyrA1</i> (<i>qnrA1</i>)	NS	NS	NS	NS	deleted RamR + OqxR:Arg93Cys + GyrA:Ser83Phe + QnrA1
Δ <i>ramR + oqxR5 + gyrA1</i> (<i>aac(6')-Ib-cr</i>)	NS	NS	NS	NS	deleted RamR + OqxR:Arg93Cys + GyrA:Ser83Phe + Aac(6')-Ib-cr

Quintuple acquisition event

Δ <i>ramR + oqxR5 + gyrA1</i> (<i>qnrA1 + aac(6')-Ib-cr</i>)	NS	NS	NS	NS	deleted RamR + OqxR:Arg93Cys + GyrA:Ser83Phe + QnrA1 + Aac(6')-Ib-cr
--	----	----	----	----	--

^a *K. pneumoniae* Ecl8 is the parental strain in all cases.

^b CIP, ciprofloxacin; LEV, levofloxacin; NOR, norfloxacin; OFL, ofloxacin

Zone diameter values for definition of susceptible (S) /non-susceptible (NS) designation were the means of three repetitions rounded to the nearest integer. Definitions were made by reference to susceptibility breakpoints set by the CLSI (29).

Table S5: Initial predictive rules and “reduced permeability correction” for ciprofloxacin susceptibility in *K. pneumoniae*

Rule number	Mutations identified in proteins			Presence of PMQR		Phenotype	“RP” Phenotype
	GyrA QRDR	OqxR	RamR	Qnr	Aac(6')-Ib-cr	(MIC [mg.mL ⁻¹])	
1	+					S (0.25)	S (1)
2		+				S (0.25)	S (1)
3			+			S (0.125)	S (0.5)
4				+		S (0.063)	S (0.25)
5					+	S (0.016)	S (0.063)
6	+	+				NS	NS
7	+		+			NS	NS
8	+			+		S (1)	NS (4)
9	+				+	S (0.5)	NS (2)
10		+	+			S (0.25)	S (1)
11		+		+		NS	NS
12		+			+	S (0.5)	NS (2)
13			+	+		NS	NS
14			+		+	S (0.063)	S (0.25)
15				+	+	S (0.5)	NS (2)
16	+	+	+			NS	NS
17	+	+		+		NS	NS
18	+	+			+	NS	NS

19	+		+	+		NS	NS
20	+		+		+	NS	NS
21	+			+	+	NS	NS
22		+	+	+		NS	Ns
23		+	+		+	S (1)	NS (4)
24		+		+	+	NS	NS
25			+	+	+	NS	NS
26	+	+	+	+		NS	NS
27	+	+	+		+	NS	NS
28	+	+		+	+	NS	NS
29	+		+	+	+	NS	NS
30		+	+	+	+	NS	NS
31	+	+	+	+	+	NS	NS

+, mutation identified or PMQR present, blank; no mutation or PMQR absent, NS (Non-susceptible) and shaded blue. S; susceptible and not shaded as defined in Table S4

“RP” (Reduced Permeability) rules to be applied when the OmpF:OmpC ratio is <0.5.

MICs were determined when isolates were designated susceptible, RP correction is 4-fold, as described in the text. Susceptibility breakpoints applied for these isolates are MIC breakpoints defined by CLSI (29).

Table S6: Final predictive rules for ciprofloxacin susceptibility in *K. pneumoniae* clinical isolates.

Rule number	Mutations identified in proteins				Presence of PMQR		Phenotype (MIC [mg.mL ⁻¹])
	1st GyrA QRDR	2 nd QRDR (ParC or GyrA)	OqxR	RamR	Qnr	Aac(6')-Ib-cr	
1RP	+						S (1)
2RP			+				S (1)
3RP				+			S (0.5)
4RP					+		S (0.25)
5RP						+	S (0.063)
6RP	+		+				NS
7RP	+			+			NS
8RP	+				+		NS (4)
9RP	+					+	NS (2)
10RP			+	+			S (1)
11RP			+		+		NS
12RP			+			+	NS (2)
13RP				+	+		NS
14RP				+		+	S (0.25)
15RP					+	+	NS (2)
16RP	+		+	+			NS
17RP	+		+		+		NS

18RP	+		+			+	NS
19RP	+			+	+		NS
20RP	+			+		+	NS
21RP	+				+	+	NS
22RP			+	+	+		Ns
23RP			+	+		+	NS (4)
24RP			+		+	+	NS
25RP				+	+	+	NS
26RP	+		+	+	+		NS
27RP	+		+	+		+	NS
28RP	+		+		+	+	NS
29RP	+			+	+	+	NS
30RP			+	+	+	+	NS
31RP	+		+	+	+	+	NS
32RP	+	+					NS (4)
33RP	+	+	+				NS
34RP	+	+		+			NS
35RP	+	+			+		NS
36RP	+	+				+	NS
37RP	+	+	+	+			NS
38RP	+	+	+		+		NS
39RP	+	+	+			+	NS
40RP	+	+		+	+		NS

41RP	+	+		+		+	NS
42RP	+	+			+	+	NS
43RP	+	+	+	+	+		NS
44RP	+	+	+	+		+	NS
45RP	+	+	+		+	+	NS
46RP	+	+		+	+	+	NS
47RP	+	+	+	+	+	+	NS

+, mutation identified or PMQR present, blank; no mutation or PMQR absent,

NS (Non-susceptible) and shaded blue. S; susceptible and not shaded

Supplementary References

- S1. Fu Y, Zhang W, Wang H, Zhao S, Chen Y, Meng F, Zhang Y, Xu H, Chen X, Zhang F. 2013. Specific patterns of gyr A mutations determine the resistance difference to ciprofloxacin and levofloxacin in *Klebsiella pneumoniae* and *Escherichia coli*. *BMC Infect Dis* 13:8.
- S2. Bialek-Davenet S, Lavigne J-P, Guyot K, Mayer N, Tournebize R, Brisse S, Leflon-Guibout V, Nicolas-Chanoine M-H. 2015. Differential contribution of AcrAB and OqxAB efflux pumps to multidrug resistance and virulence in *Klebsiella pneumoniae*. *J Antimicrob Chemother* 70:81–8.
- S3. Hentschke M, Wolters M, Sobottka I, Rohde H, Aepfelbacher M. 2010. ramR mutations in clinical isolates of *Klebsiella pneumoniae* with reduced susceptibility to tigecycline. *Antimicrob Agents Chemother* 54:2720–3.